CTRI Number |
CTRI/2022/10/046929 [Registered on: 31/10/2022] Trial Registered Prospectively |
Last Modified On: |
28/10/2022 |
Post Graduate Thesis |
Yes |
Type of Trial |
Observational |
Type of Study
|
Follow Up Study |
Study Design |
Other |
Public Title of Study
|
Difference in the distance walked in six minute walk test before and after radiation therapy in breast cancer patients |
Scientific Title of Study
|
Estimating the minimally clinical important difference of six minute walk distance in patients with breast cancer |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
Nil |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Gouri Elurker |
Designation |
MPT |
Affiliation |
Father Muller Medical College |
Address |
Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore
Dakshina Kannada
Karnataka
575002
India
Dakshina Kannada KARNATAKA 575002 India |
Phone |
7447240180 |
Fax |
|
Email |
gaurielurker@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Prof Cherishma Dsilva |
Designation |
Professor |
Affiliation |
Father Muller Medical College |
Address |
Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore
Dakshina Kannada
Karnataka
575002
India
Dakshina Kannada KARNATAKA 575002 India |
Phone |
9663558311 |
Fax |
|
Email |
cheri8585@fathermuller.in |
|
Details of Contact Person Public Query
|
Name |
Gouri Elurker |
Designation |
MPT |
Affiliation |
Father Muller Medical College |
Address |
Father Muller Medical College, Physiotherapy Department, Kankanady, Mangalore
Dakshina Kannada
Karnataka
575002
India
Dakshina Kannada KARNATAKA 575002 India |
Phone |
7447240180 |
Fax |
|
Email |
gaurielurker@gmail.com |
|
Source of Monetary or Material Support
|
Father Muller Medical College, Kankanady, Mangalore,Dakshina Kannada,Karnataka 575002 |
|
Primary Sponsor
|
Name |
Father Muller Medical College |
Address |
Father Muller Medical College,Kankanady,Dakshina kannada,Mangalore,Karnataka 575002 |
Type of Sponsor |
Private medical college |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Gouri Elurker |
Father Muller Medical College |
Department of physiotherapy,Dakshina kannada,Karnataka Dakshina Kannada KARNATAKA |
7447240180
gaurielurker@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Father Muller Institutional Ethics Committee(FMIEC) |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Nil |
Nil |
|
Inclusion Criteria
|
Age From |
19.00 Year(s) |
Age To |
75.00 Year(s) |
Gender |
Both |
Details |
patients diagnosed with breast cancer stage 3-4 receiving chemo-radiation therapy.
all genders.
age: 19-75 years. |
|
ExclusionCriteria |
Details |
Cardiovascular conditions such as coronary artery disease, uncontrolled angina, ischemic heart disease.
neurological condition such as stroke, Parkinson disease, Guillain barre syndrome.
Musculoskeletal condition such as dislocation, strain, sprain.
Hb count <8mg/dL.
Inability to comply with study procedure. |
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Not Applicable |
Primary Outcome
|
Outcome |
TimePoints |
six minute walk test |
baseline and 16 weeks post radiation therapy |
|
Secondary Outcome
|
Outcome |
TimePoints |
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ)-30 |
baseline and 16 weeks post radiation therapy |
|
Target Sample Size
|
Total Sample Size="40" Sample Size from India="40"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
05/11/2022 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
Nil |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
Need for the study: Breast cancer is most frequently diagnosed and one of the leading cancers amongst women worldwide. Breast cancer arises when there is growth of the malignant or cancer-causing cells in either ducts or lobules of the breast. Lump in the breast, change in the size of breast, fluid discharge from the nipple, dimpling of the skin and red or scaly patch on the breast can be the signs of breast carcinoma. Certain risk factors associated with breast cancer includes obesity, physical inactivity, alcohol, early menarche and late menopause, family history and BRCA1/ BRCA2 gene mutation. According to the site invaded by cancerous cells, breast cancer can be either invasive type which means that it is limited to one part and non-invasive type that is spreading to the other parts. Non-invasive type includes lobular carcinoma (developing in breast lobules) and ductal carcinoma (developing in breast ducts) whereas invasive type includes infiltrating lobular carcinoma, infiltrating ductal carcinoma, medullary carcinoma, mucinous carcinoma and tubular carcinoma. Early detection and treatment increase the rate of survival of cancer patients, hence every woman should get themselves screened for breast cancer atleast once a year. Different diagnostic methods available for cancer diagnosis include mammography, needle biopsy of breast, ultrasound, PET scan (positron emission tomography), MRI and most importantly self-examination. Early intervention and treatment techniques of chemotherapy, radiation therapy, surgery and hormone therapy can help an individual lower the risks and spreading of the cancer. Chemotherapy is the administration of drugs to destroy the cancer cells and is given before surgery and is continued after surgery too. Surgery is either total mastectomy or radical mastectomy. In total mastectomy whole breast is removed whereas in radical mastectomy only the cancerous region from the breast is removed preserving the other breast tissue. Another method used is radiation therapy that destroy the microscopic tumor cells, this is often followed by surgical management, it can be either external beam radiotherapy or internal radiotherapy. Hormone therapy is used mainly when some cancer cells require estrogen for its growth, hence through hormone therapy estrogen receptors are block to prevent the growth of these cells. Cancer patients undergoing treatment will pursue various side effects like nausea, vomiting, weight gain, sleep disturbance, fatigue and various heart related problems. These symptoms eventually affect their quality of living making a negative impact on their day-to-day activities. Fatigue has major impact on a person’s physical, social and emotional dimension on quality of life along with other factors such as age, educational level, stage of the cancer and diagnosis of the disease itself. European Organization for Research and Treatment of Cancer (EORTC) has created several questionnaires to assess the Quality of Life (QOL) of cancer patients which is available in different languages. QLQ-30 is one of the questionnaires used to study about the QOL in breast cancer patients over past week which includes 30 items. Questionnaire contains functional scale, symptom scale and Global health status/QOL scale. 6 Minute Walk Test(6MWT) is an assessment tool for measuring functional capacity of an individual. There requires no equipment but only a straight hard pathway of 100ft to perform the test. Indicated to measure exercise capacity in patients or response to any medical intervention. Test to be avoided on individuals having angina or myocardial infarction in recent time of past few months or hypertensive patients (>180/100mmHg). Distance covered by the individual at the end of 6 minutes has to be noted along with the perceived exertion on Borgs scale. Minimally clinical important difference (MCID) is a clinical measure to assess the changes in one’s treatment outcome which an individual identifies as important. MCID is calculated by distribution-based method and anchor-based method. Data in distribution-based method relies on standard deviation, standard error of the mean change and standard deviation of stable group whereas anchor-based method depends upon the changes reported by the patient. Chemotherapy induced complications such as decline in cardiopulmonary fitness has major impact on QOL in patients with breast cancer. 6MWT is used as an outcome tool to assess functional capacity and has strong correlation to QOL. As per our knowledge there is no evidence estimating MCID of patients with breast cancer undergoing chemotherapy, hence this justifies the need to conduct the study. RESEARCH QUESTION Is there any MCID in 6 MWD in breast cancer patients from the baseline (pretreatment) and after 16 weeks? HYPOTHESIS (H1): There will be MCID in 6MWD in breast cancer patients from baseline (pretreatment) to 16 weeks after beginning with chemotherapy treatment. NULL HYPOTHESIS (H0): There will be no MCID in 6MWD in breast cancer patients from baseline (pretreatment) to 16 weeks after beginning chemotherapy treatment. |